Latest Regulatory News

Element 25 Limited has made significant strides in advancing its Butcherbird Expansion Project in Western Australia, securing $60 million in funding and progressing key engineering and contract milestones. Simultaneously, the company moves closer to finalising financing for its US-based battery-grade manganese refinery.

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Meteoric Resources has cleared a major regulatory hurdle with the approval of its Preliminary Environmental License for the Caldeira Rare Earths Project, enabling the company to progress towards construction and first production targeted for 2028. The company also commissioned its pilot plant, producing its first batches of rare earth carbonate.

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.

5E Advanced Materials has filed a Form S-1 registration with the SEC to raise up to $30 million through a common stock offering, aiming to advance its Fort Cady boron and lithium project. The capital raise is critical as the company navigates development milestones and financial challenges.

ASX Limited has updated its FY26 expense growth guidance upwards, reflecting increased investments in risk management and technology modernisation alongside ASIC Inquiry-related costs, while reporting strong unaudited 1H26 revenue growth.

Iron Road Ltd maintained modest spending on its Central Eyre Iron Project while progressing exploration at the Mulgathing Project, with key drilling results awaited. The company also updated its strategic land options at Cape Hardy amid subdued steel market conditions.

Imricor Medical Systems has achieved multiple world-first procedures using real-time MRI guidance for cardiac ablation, advancing clinical trials and regulatory progress amid a strategic commercial expansion.

Radiopharm Theranostics has reported promising interim results from its Phase 2b trial of RAD 101, showing high concordance with MRI in brain metastases patients, while progressing multiple other clinical programs and securing a strong cash position to fund operations into 2027.

Megado Minerals is poised to advance its Iberian Copper Project with investigation permits expected early 2026, setting the stage for airborne geophysics and maiden drilling. Meanwhile, the company maintains strong positions in Canadian lithium and gold assets.

Emerald Resources NL has announced a significant update to its Dingo Range Gold Project in Western Australia, increasing its mineral resource to 1.41 million ounces of gold and securing full mining permits ahead of planned development in 2026.

Epiminder Limited has successfully listed on the ASX, raising $125 million to commercialise its FDA-approved Minder device. The company has initiated the first US implant and secured five leading medical centres for its DETECT study.